Medicine and HealthNature Medicine
p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial
H. R. C. Shanks, K. Chen, et al.
Exciting research by Hayley R. C. Shanks and colleagues investigates the p75 neurotrophin receptor in Alzheimer's disease, revealing that the novel small molecule LM11A-31 potentially slows the disease's progression, despite no significant cognitive improvements. This work opens new avenues for treatment exploration.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Effects of Nordic walking in Alzheimer's disease: A single-blind randomized controlled clinical trial
A. Angiolillo, D. Leccese, et al.
Medicine and Health
A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease
R. Cheng, L. Wang, et al.
Medicine and Health
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
A. J. Sanyal, L. M. Kaplan, et al.
Medicine and Health
RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial
R. Wittoek, G. Verbruggen, et al.
